儿童T系急性淋巴细胞白血病与PI3K-Akt-mTOR信号通路抑制剂的相关研究进展  

Advances in childhood T-cell acute lymphoblastic leukemia and inhibitors targeting PI3K-Akt-mTOR signaling pathway

作　　者：罗丹青[1] 王建华[2] 师晓东[1] 

机构地区：[1]首都儿科研究所附属儿童医院血液科,北京100020 [2]首都儿科研究所生物技术室儿童发育营养组学北京市重点实验室,北京100200

出　　处：《白血病．淋巴瘤》2017年第6期380-384,共5页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81571443）

摘　　要：T系急性淋巴细胞白血病（T-ALL）是T系前体细胞发生恶性转化致造血系统恶性病变的一种侵袭性肿瘤.发病率占儿童ALL的15%.研究发现PI3K-Akt-mTOR信号通路与T-ALL发生,白血病细胞增殖、细胞凋亡抑制和细胞耐药相关.通过使用PI3K-Akt-mTOR信号通路抑制剂治疗T-ALL儿童患者,能有针对性地靶向抑制T-ALL细胞,发挥有效的细胞毒作用.通过缩短疾病疗程,提高儿童T-ALL患者的生命质量,减少疾病复发,为传统化疗方案抵抗儿童T-ALL患者提供一种更有效的疾病干预方法.T-cell acute lymphoblastic leukemia （T-ALL） is a hematopoietic malignancy derived from T precursor cells. Morbidity of children accounted for 15%of ALL. Studies have found that PI3K-Akt-mTOR signaling pathway is associated with the occurrence of T-ALL, cell proliferation, cell apoptosis and drug resistance. The PI3K-Akt-mTOR signaling pathway inhibitors, which can target to inhibit T-ALL cell proliferation in the treatment of T-ALL children, plays an effective cytotoxic role. By shortening the duration of treatment, it can significantly improve the quality of life of children with T-ALL and reducing disease recurrence. It is a more effective way for traditional chemotherapy resistant T-ALL children patients.

关 键 词：白血病  T细胞 儿童 拮抗剂 P13K-AKT-mTOR信号通路 

分 类 号：R733.71[医药卫生—肿瘤]